Savient faces bankruptcy after Krystexxa sales disappoint - PMLiVE

10/16/13


Drug Discovery & Development

Savient faces bankruptcy after Krystexxa sales disappoint
PMLiVE
US pharma company Savient Pharmaceuticals has filed for bankruptcy and is set to sell most of its assets for $55m. The Chapter 11 filing is primarily down to continued disappointing sales of Savient's lead product, gout treatment Krystexxa (pegloticase ...
Gout Drug's Sales Flop Lands Savient Pharma in Chapter 11Xconomy
Savient Pharmaceuticals Starts Chapter 11 Bankruptcy ProceedingsWall Street Journal
Savient Pharmaceuticals Commences Voluntary Chapter 11 Proceeding; Seeks ...PR Newswire (press release)
Law360 (subscription)
all 27 news articles »

[more]